Investors seeking robust dividend-paying equities frequently turn to Dividend Kings, a select group of companies that have consistently increased their shareholder distributions for at least five decades. This article delves into a comparison between two prominent healthcare giants in this esteemed category: Abbott Laboratories and Johnson & Johnson. While both boast impressive dividend streaks, their recent market trajectories have diverged. Johnson & Johnson has outperformed the broader market, whereas Abbott Laboratories has lagged behind. This analysis aims to determine which of these long-standing dividend payers offers a more attractive investment opportunity today.
Healthcare Giants: A Deeper Dive into Abbott and Johnson & Johnson's Investment Appeal
For discerning investors, the choice between Abbott Laboratories and Johnson & Johnson presents a nuanced decision. Abbott Laboratories, a medical device specialist, has recently grappled with setbacks, including stagnant revenue and earnings growth in its diagnostics and nutrition divisions, alongside legal and regulatory hurdles stemming from lawsuits related to its infant formula. Despite these challenges, Abbott's strong medical device portfolio, particularly its diabetes care unit featuring the FreeStyle Libre continuous glucose monitoring system, continues to drive significant growth. Moreover, its recent $21 billion acquisition of Exact Sciences, bringing the Cologuard colorectal cancer diagnostic test under its wing, is poised to unlock new opportunities in the expanding cancer diagnostic market. Abbott has proudly maintained its dividend increases for an impressive 54 consecutive years.
In contrast, Johnson & Johnson has demonstrated remarkable resilience and growth. Even with the impending loss of U.S. patent exclusivity for its immunosuppressant, Stelara, in 2025, and governmental pressures on drug pricing, the pharmaceutical powerhouse continues to thrive. Bolstered by its extensive array of pharmaceutical products, the company anticipates generating over $100 billion in sales this year, a significant milestone in the biopharmaceutical industry. Recent advancements, such as the approval of Icotyde—an innovative oral drug for plaque psoriasis—and the clearance of Ottava, a robotic-assisted surgery (RAS) system, further solidify Johnson & Johnson's market position. The RAS market, though nascent, holds substantial promise for future expansion, offering quicker recovery times and shorter hospital stays for patients. Furthermore, Johnson & Johnson has made significant strides in resolving numerous lawsuits concerning its talc-based products. With an outstanding record of 64 consecutive years of dividend increases, Johnson & Johnson stands as a beacon of reliability for income-seeking investors.
When weighing these two healthcare stalwarts, Johnson & Johnson emerges as the more compelling investment. While both companies are undeniably robust choices for long-term income generation, Johnson & Johnson's consistently higher revenue and earnings, coupled with its superior dividend growth history, set it apart. Although Johnson & Johnson trades at a slightly higher forward earnings multiple (23x compared to Abbott's 20.7x), its stronger foundational business and brighter future prospects justify this premium. The company's strategic advancements in pharmaceuticals and medical technology underscore its enduring potential for sustained growth and shareholder value. Ultimately, for those prioritizing stability, innovation, and an exceptional dividend track record, Johnson & Johnson presents a more attractive proposition in the current market landscape.
